---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-310054"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2022-12-21T23:59:59+00:00"
generated_at: "2026-06-21T00:39:45.430130+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# BioMarin adopts amended bylaws with DGCL alignment and universal proxy rule updates

## Summary
- Board approved amended bylaws effective Dec 15, 2022, updating notice and meeting adjournment to align with DGCL.
- Requires stockholders soliciting proxies to use a proxy card color other than white.
- Amends procedural mechanics for stockholder nominations and proposals under SEC Rule 14a-19 (Universal Proxy Rules).
- Includes administrative, modernizing, and clarifying changes to the bylaws.

## SEC filing metadata
- accession: 0001193125-22-310054
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2022-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312522310054/0001193125-22-310054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312522310054/d440213d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-310054
- JSON: https://secwatch.observer/filing/0001193125-22-310054.json
- Plain text: https://secwatch.observer/filing/0001193125-22-310054.txt

## Key facts
- Governance Changes
  BIOMARIN PHARMACEUTICAL INC: Amended and restated bylaws to update provisions related to stockholder meetings, proxy rules, and other administrative changes (effective 2022-12-15).
  - Change: bylaw amendment
  - Effective: 2022-12-15
  source text: On December 15, 2022, the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) approved and adopted the Company’s Amended and Restated Bylaws (as so amended, the “Amended Bylaws”), effective as of December 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312522310054/0001193125-22-310054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.